Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Next Previous
Trial Profile

A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Plamotamab (Primary) ; Tafasitamab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Xencor

Most Recent Events

  • 10 Mar 2023 Status changed from recruiting to discontinued as the company stopped development of the tidutamab and XmAb841 programs and also stopped development of plamotamab, tafasitamab and lenalidomide combination study
  • 09 Jan 2023 According to Xencor media release, the company is winding down and ending the enrollment in this study due to challenges with patient accrual in lymphoma.
  • 17 Jun 2022 Trial design presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top